Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:10377007rdf:typepubmed:Citationlld:pubmed
pubmed-article:10377007lifeskim:mentionsumls-concept:C0332307lld:lifeskim
pubmed-article:10377007lifeskim:mentionsumls-concept:C0560175lld:lifeskim
pubmed-article:10377007lifeskim:mentionsumls-concept:C0005938lld:lifeskim
pubmed-article:10377007lifeskim:mentionsumls-concept:C0029454lld:lifeskim
pubmed-article:10377007lifeskim:mentionsumls-concept:C0443147lld:lifeskim
pubmed-article:10377007lifeskim:mentionsumls-concept:C0022877lld:lifeskim
pubmed-article:10377007lifeskim:mentionsumls-concept:C0220825lld:lifeskim
pubmed-article:10377007lifeskim:mentionsumls-concept:C1706209lld:lifeskim
pubmed-article:10377007pubmed:issue1lld:pubmed
pubmed-article:10377007pubmed:dateCreated1999-7-20lld:pubmed
pubmed-article:10377007pubmed:abstractTextType II autosomal dominant osteopetrosis (ADO2) is an inherited disorder characterized by increased skeletal mass and characteristic abnormalities evident on radiography. Although previous investigators have described nonpenetrant individuals (carriers), it is not known whether carriers manifest subtle abnormalities. We hypothesized that ADO2 carriers would have an abnormality of osteoclast function that would lead to changes in bone mineral density (BMD), in serum tartrate-resistant acid phosphatase (TRAP), or in creatine kinase isoenzyme BB (CK-BB) levels that would permit carrier recognition. We identified a female carrier in a well-established ADO2 family and measured BMD, serum TRAP, and CK-BB concentrations. She had normal BMD, serum TRAP, and CK-BB concentrations. Thus, these measurements cannot be used to exclude carrier status in individuals who are seen for genetic counseling. However, measurements in other asymptotic carriers are necessary before concluding that these measurements are normal in all or most nonpenetrant individuals.lld:pubmed
pubmed-article:10377007pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10377007pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10377007pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10377007pubmed:languageenglld:pubmed
pubmed-article:10377007pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10377007pubmed:citationSubsetIMlld:pubmed
pubmed-article:10377007pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10377007pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10377007pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10377007pubmed:statusMEDLINElld:pubmed
pubmed-article:10377007pubmed:monthJullld:pubmed
pubmed-article:10377007pubmed:issn0148-7299lld:pubmed
pubmed-article:10377007pubmed:authorpubmed-author:CooperHHlld:pubmed
pubmed-article:10377007pubmed:authorpubmed-author:WeaverD DDDlld:pubmed
pubmed-article:10377007pubmed:authorpubmed-author:TakacsIIlld:pubmed
pubmed-article:10377007pubmed:authorpubmed-author:EconsM JMJlld:pubmed
pubmed-article:10377007pubmed:issnTypePrintlld:pubmed
pubmed-article:10377007pubmed:day2lld:pubmed
pubmed-article:10377007pubmed:volume85lld:pubmed
pubmed-article:10377007pubmed:ownerNLMlld:pubmed
pubmed-article:10377007pubmed:authorsCompleteYlld:pubmed
pubmed-article:10377007pubmed:pagination9-12lld:pubmed
pubmed-article:10377007pubmed:dateRevised2007-11-15lld:pubmed
pubmed-article:10377007pubmed:meshHeadingpubmed-meshheading:10377007...lld:pubmed
pubmed-article:10377007pubmed:meshHeadingpubmed-meshheading:10377007...lld:pubmed
pubmed-article:10377007pubmed:meshHeadingpubmed-meshheading:10377007...lld:pubmed
pubmed-article:10377007pubmed:meshHeadingpubmed-meshheading:10377007...lld:pubmed
pubmed-article:10377007pubmed:meshHeadingpubmed-meshheading:10377007...lld:pubmed
pubmed-article:10377007pubmed:meshHeadingpubmed-meshheading:10377007...lld:pubmed
pubmed-article:10377007pubmed:meshHeadingpubmed-meshheading:10377007...lld:pubmed
pubmed-article:10377007pubmed:meshHeadingpubmed-meshheading:10377007...lld:pubmed
pubmed-article:10377007pubmed:meshHeadingpubmed-meshheading:10377007...lld:pubmed
pubmed-article:10377007pubmed:meshHeadingpubmed-meshheading:10377007...lld:pubmed
pubmed-article:10377007pubmed:meshHeadingpubmed-meshheading:10377007...lld:pubmed
pubmed-article:10377007pubmed:meshHeadingpubmed-meshheading:10377007...lld:pubmed
pubmed-article:10377007pubmed:meshHeadingpubmed-meshheading:10377007...lld:pubmed
pubmed-article:10377007pubmed:meshHeadingpubmed-meshheading:10377007...lld:pubmed
pubmed-article:10377007pubmed:year1999lld:pubmed
pubmed-article:10377007pubmed:articleTitleBone mineral density and laboratory evaluation of a type II autosomal dominant osteopetrosis carrier.lld:pubmed
pubmed-article:10377007pubmed:affiliationDepartment of Medicine, Indiana University School of Medicine, Indianapolis 46202, USA.lld:pubmed
pubmed-article:10377007pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:10377007pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
pubmed-article:10377007pubmed:publicationTypeCase Reportslld:pubmed
pubmed-article:10377007pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10377007lld:pubmed